Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | DCUN1D1 | Q96GG9 | 16/20 | 0.46 |
| ▸ | UBE2M | P61081 | 15/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3742866 | 0.84 | LMNA (0.48) | LMNAKMT2ADCUN1D1UBE2MALDH1A1 | |
| SCHEMBL21916114 | 0.84 | ALDH1A1 (0.59) | LMNAKMT2ADCUN1D1UBE2MALDH1A1 | |
| SCHEMBL21915933 | 0.83 | LMNA (0.49) | LMNAKMT2ADCUN1D1UBE2MALDH1A1 | |
| SCHEMBL21916782 | 0.82 | LMNA (0.47) | LMNAKMT2ADCUN1D1UBE2MALDH1A1 | |
| SCHEMBL21916326 | 0.82 | ALDH1A1 (0.53) | LMNAKMT2ADCUN1D1UBE2MALDH1A1 | |
| SCHEMBL9479999 | 0.81 | LMNA (0.64) | LMNAKMT2ADCUN1D1UBE2MALDH1A1 | |
| SCHEMBL21915932 | 0.81 | ALDH1A1 (0.46) | LMNAKMT2ADCUN1D1UBE2MALDH1A1 | |
| SCHEMBL22423528 | 0.81 | ALDH1A1 (0.51) | LMNAKMT2ADCUN1D1UBE2MALDH1A1 | |
| SCHEMBL19361713 | 0.81 | DCUN1D1 (0.52) | LMNAKMT2ADCUN1D1UBE2MALDH1A1 | |
| SCHEMBL21916042 | 0.80 | CYP27B1 (0.45) | LMNAKMT2ADCUN1D1UBE2MALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004101572-A1 | 7-GLUTARYL IMIDE CEPHALOSPORANIC ACID DERIVATIVES AND PROCESS FOR PREPARING IT | CKD BIO CORPORATION (KR) | 2004-11-25 | — | — | WO | claimed |
| US-6420554-B1 | REACTION OF BETA LACTAM WITH PHOSPHOROUS HALIDE IN THE PRESENCE OF BASE, ADDING PHENOL, REACTION WITH ALCOHOL AND REMOVAL OF ESTER | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 2002-07-16 | — | — | US | claimed |
| EP-3225627-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Northwest University (CN) | 2017-10-04 | — | — | EP | disclosed |
| US-20170267718-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | NORTHWEST UNIVERSITY (CN) | 2017-09-21 | — | — | US | disclosed |
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| WO-2004101572-A1 | 7-GLUTARYL IMIDE CEPHALOSPORANIC ACID DERIVATIVES AND PROCESS FOR PREPARING IT | CKD BIO CORPORATION (KR) | 2004-11-25 | — | — | WO | disclosed |
| US-20030186924-A1 | Prodrugs | MEDIVIR AB | 2003-10-02 | — | — | US | disclosed |
| EP-0209751-A2 | Cephalosporin derivatives and bactericides containing the same | MEIJI SEIKA KAISHA LTD. (JP) | 1987-01-28 | — | — | EP | disclosed |
| US-4616008-A | LIPID-SOLUBLE CEPHALOSPORINS AND CYCLODEXTRINS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-10-07 | — | — | US | disclosed |
| EP-0042026-B1 | 3,4-DISUBSTITUTED AZETIDIN-2-ON COMPOUNDS AND PROCESS FOR THEIR PREPARATION | CIBA-GEIGY AG (CH) | 1986-01-08 | — | — | EP | disclosed |
| EP-0163433-A2 | Antibacterial solid composition for oral administation | Takeda Chemical Industries, Ltd. (JP) | 1985-12-04 | — | — | EP | disclosed |
| EP-0108627-A2 | Cephalosporin derivatives and process for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-05-16 | — | — | EP | disclosed |
| EP-0042026-A1 | 3,4-Disubstituted azetidin-2-on compounds and process for their preparation | CIBA-GEIGY AG (CH) | 1981-12-23 | — | — | EP | disclosed |
| US-4263280-A | OF ANTIBIOTICS CEFSULODIN SODIUM, GENTAMYCIN C | CIBA-GEIGY CORPORATION (US) | 1981-04-21 | — | — | US | disclosed |
| EP-0004925-A1 | Synergistic mixtures of antibiotics and process for their production | CIBA-GEIGY AG (CH) | 1979-10-31 | — | — | EP | disclosed |
| EP-0003960-A1 | 6-Substituted thia-aza-compounds, their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1979-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | LMNA 2899/4885KMT2A 3465/4885DCUN1D1 4137/4885 |
| US-20030186924-A1 | Prodrugs | HAVCR2, CYP7A1, IGSF11 | LMNA 2190/4885KMT2A 4375/4885DCUN1D1 3297/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | LMNA 2899/4885KMT2A 3465/4885DCUN1D1 4137/4885 |
| US-20170267718-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | VIP, PREP, ACE | LMNA 905/4885KMT2A 4494/4885DCUN1D1 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.